Effect of a synbiotic containing Lactobacillus rhamnosus GG and fructooligosaccharides on the dynamics of the level of fecal calprotectin in children of first year of life

Cover Page


Cite item

Full Text

Abstract

Rationale: As clinical efficacy of probiotics and prebiotics is determined by their joint effects both on the mechanism of immune tolerance, gut inflammation and intestinal wall permeability, one of the objective methods to assess efficacy of probiotic strain-containing agents could be based on measurement of fecal calprotectin levels.

Aim: To evaluate changes in fecal calprotectin as an efficacy parameter of treatment with the Lactobacillus rhamnosus GG  – fructooligosacсharide complex for prevention of atopic dermatitis in infants.

Materials and methods: Sixty healthy newborns from the risk group for allergic disorders were randomized (envelope randomization) into two groups: the infants from the control group (n = 31) were given widely used recommendations to prevent atopic dermatitis, whereas the infants from the study group (n = 29) were additionally administered a synbiotic containing Lactobacillus rhamnosus GG with fructooligosaccharides. The efficacy of the synbiotic therapy was assessed by measurement of fecal calprotectin levels at 3 and 6  months of the follow-up.

Results: The first measurement of fecal calprotectin levels at 3 months showed its significant increase in all infants (mean 276.9 ± 128.8  mcg/G), compared to the normal range (below 50  mcg/G). The second measurement at 6  months demonstrated a  decrease in fecal calprotectin in infants from both groups (mean 75.8 ± 55.3 mcg/G). However, mean levels of fecal calprotectin in the infants from the study group who had been administered the synbiotic, was significantly lower than that in the control group (48.6 ± 38.5 and 99.7 ± 57.4  mcg/G, respectively; р < 0.05).

Conclusion: The observed changes in fecal calprotectin levels support the positive role of synbiotics and lyophilized complex of Lactobacillus rhamnosus GG with fructooligosaccharides in the growth of gut microbiota in infants and in the reduction of inflammation, all of this being an important prerequisite for development of the oral tolerance mechanisms.

About the authors

N. B. Migacheva

Samara State Medical University

Author for correspondence.
Email: nbmigacheva@gmail.com
MD, PhD, Associate Professor, Chair of Pediatrics, Institute for Professional Education, 195–140 Novo-Vokzal'naya ul., Samara, 443084 Россия

D. V. Pechkurov

Samara State Medical University

Email: fake@neicon.ru

MD, PhD, Professor, Head of the Chair of Pediatric Diseases,

89 Chapaevskaya ul., Samara, 443099

Россия

T. I. Kaganova

Samara State Medical University

Email: fake@neicon.ru

MD, PhD, Professor, Head of the Chair of Pediatrics, Institute for Professional Education,

89 Chapaevskaya ul., Samara, 443099

Россия

T. V. Sushkova

Samara City Children's Clinical Hospital No. 1 named after N.N. Ivanova

Email: fake@neicon.ru

MD, Pediatrician,

165А K. Marksa pr-t, Samara, 443079

Россия

References

  1. Li D, Wang P, Wang P, Hu X, Chen F. The gut microbiota: A treasure for human health. Biotechnol Adv. 2016;34(7):1210–24. doi: 10.1016/j.biotechadv.2016.08.003.
  2. Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM, Mayer EA. An update on the use and investigation of probiotics in health and disease. Gut. 2013;62(5): 787–96. doi: 10.1136/gutjnl-2012-302504.
  3. Cardile S, Alterio T, Arrigo T, Salpietro C. Role of prebiotics and probiotics in pediatric diseases. Minerva Pediatr. 2016;68(6):487–97.
  4. Prescott S, Nowak-Węgrzyn A. Strategies to prevent or reduce allergic disease. Ann Nutr Metab. 2011;59 Suppl 1:28–42. doi: 10.1159/000334150.
  5. Sommer F, Bäckhed F. The gut microbiota – masters of host development and physiology. Nat Rev Microbiol. 2013;11(4):227–38. doi: 10.1038/nrmicro2974.
  6. Prescott SL, Björkstén B. Probiotics for the prevention or treatment of allergic diseases. J Allergy Clin Immunol. 2007;120(2):255–62. doi: 10.1016/j.jaci.2007.04.027.
  7. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, Zaat BA, Yazdanbakhsh M, Wierenga EA, van Kooyk Y, Kapsenberg ML. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. 2005;115(6):1260–7. doi: 10.1016/j.jaci.2005.03.036.
  8. Houghteling PD, Walker WA. Why is initial bacterial colonization of the intestine important to infants' and children's health? J Pediatr Gastroenterol Nutr. 2015;60(3):294– 307. doi: 10.1097/MPG.0000000000000597.
  9. Kim JY, Kwon JH, Ahn SH, Lee SI, Han YS, Choi YO, Lee SY, Ahn KM, Ji GE. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr Allergy Immunol. 2010;21(2 Pt 2):e386–93. doi: 10.1111/j.1399-3038.2009.00958.x.
  10. Zuccotti G, Meneghin F, Aceti A, Barone G, Callegari ML, Di Mauro A, Fantini MP, Gori D, Indrio F, Maggio L, Morelli L, Corvaglia L; Italian Society of Neonatology. Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis. Allergy. 2015;70(11): 1356–71. doi: 10.1111/all.12700.
  11. Kuitunen M, Kukkonen K, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Haahtela T, Savilahti E. Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. J Allergy Clin Immunol. 2009;123(2):335–41. doi: 10.1016/j.jaci.2008.11.019.
  12. Kim NY, Ji GE. Effects of probiotics on the prevention of atopic dermatitis. Korean J Pediatr. 2012;55(6):193–201. doi: 10.3345/kjp.2012.55.6.193.
  13. Arslanoglu S, Moro GE, Schmitt J, Tandoi L, Rizzardi S, Boehm G. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. J Nutr. 2008;138(6):1091–5.
  14. Grüber C, van Stuijvenberg M, Mosca F, Moro G, Chirico G, Braegger CP, Riedler J, Boehm G, Wahn U; MIPS 1 Working Group. Reduced occurrence of early atopic dermatitis because of immunoactive prebiotics among low-atopy-risk infants. J Allergy Clin Immunol. 2010;126(4): 791–7. doi: 10.1016/j.jaci.2010.07.022.
  15. Sjögren YM, Tomicic S, Lundberg A, Böttcher MF, Björkstén B, Sverremark-Ekström E, Jenmalm MC. Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses. Clin Exp Allergy. 2009;39(12):1842–51. doi: 10.1111/j.1365-2222.2009.03326.x.
  16. Theede K, Kiszka-Kanowitz M, Nordgaard-Lassen I, Nielsen AM. Faecal calprotectin is a useful biomarker for intestinal inflammation. Ugeskr Laeger. 2014;176(37). pii: V04140213.
  17. Li F, Ma J, Geng S, Wang J, Liu J, Zhang J, Sheng X. Fecal calprotectin concentrations in healthy children aged 1–18 months. PLoS One. 2015;10(3):e0119574. doi: 10.1371/journal.pone.0119574.
  18. Orivuori L, Mustonen K, de Goffau MC, Hakala S, Paasela M, Roduit C, Dalphin JC, Genuneit J, Lauener R, Riedler J, Weber J, von Mutius E, Pekkanen J, Harmsen HJ, Vaarala O; PASTURE Study Group. High level of fecal calprotectin at age 2 months as a marker of intestinal inflammation predicts atopic dermatitis and asthma by age 6. Clin Exp Allergy. 2015;45(5):928–39. doi: 10.1111/cea.12522.
  19. Li F, Ma J, Geng S, Wang J, Ren F, Sheng X. Comparison of the different kinds of feeding on the level of fecal calprotectin. Early Hum Dev. 2014;90(9):471–5. doi: 10.1016/j.earlhumdev.2014.06.005.
  20. Mendall MA, Chan D, Patel R, Kumar D. Faecal calprotectin: factors affecting levels and its potential role as a surrogate marker for risk of development of Crohn's Disease. BMC Gastroenterol. 2016;16(1):126. doi: 10.1186/s12876-016-0535-z.
  21. Mohan R, Koebnick C, Schildt J, Mueller M, Radke M, Blaut M. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr Res. 2008;64(4): 418–22. doi: 10.1203/PDR.0b013e318181b7fa.
  22. Нетребенко ОK, Корниенко EA, Кубалова СC. Использование пробиотиков у детей с кишечными коликами. Педиатрия. Журнал им. Г.Н. Сперанского. 2014;93(4):86–93.
  23. Fallahi G, Motamed F, Yousefi A, Shafieyoun A, Najafi M, Khodadad A, Farhmand F, Ahmadvand A, Rezaei N. The effect of probiotics on fecal calprotectin in patients with cystic fibrosis. Turk J Pediatr. 2013;55(5):475–8.
  24. Moussa R, Khashana A, Kamel N, Elsharqawy SE. Fecal calprotectin levels in preterm infants with and without feeding intolerance. J Pediatr (Rio J). 2016;92(5):486–92. doi: 10.1016/j.jped.2015.11.007.
  25. Winberg A, Nagaeva O, Nagaev I, Lundell C, Arencibia I, Mincheva-Nilsson L, Rönmark E, West CE. Dynamics of cytokine mRNA expression and fecal biomarkers in school-children undergoing a double-blind placebo-controlled food challenge series. Cytokine. 2016;88:259–66. doi: 10.1016/j.cyto.2016.09.014.
  26. Trillo Belizón C, Ortega Páez E, Medina Claros AF, Rodríguez Sánchez I, Reina González A, Vera Medialdea R, Ramón Salguero JM. Faecal calprotectin as an aid to the diagnosis of non-IgE mediated cow's milk protein allergy. An Pediatr (Barc). 2016;84(6):318–23. doi: 10.1016/j.anpedi.2015.07.007.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Migacheva N.B., Pechkurov D.V., Kaganova T.I., Sushkova T.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies